Protara Therapeutics stockholders elect directors and approve equity plan at 2025 annual meeting

Protara Therapeutics, Inc.

Stockholders elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors with 17.7M, 22.1M, and 22.1M votes for, respectively.
Ratification of Ernst & Young as independent auditor for fiscal 2025 was approved with 29.3M votes for, 147,664 against, 327,362 abstentions.
Advisory vote on executive compensation passed with 20.4M for, 134,110 against, 2.1M abstentions, and 7.2M broker non-votes.
Amendment to the 2024 Equity Incentive Plan was approved with 21.3M for, 907,425 against, 365,697 abstentions, and 7.2M broker non-votes.
Over 38.5M shares were outstanding as of the April 16, 2025 record date; meeting held June 11, 2025.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.